Mark R. Burge, MD, is an established clinical and translational investigator in diabetes at the University of New Mexico HSC.  His R01-funded studies have thus far focused on the physiology and pathophysiology of hypoglycemia in patients with type 2 diabetes and on improving treatments for individuals with type 1 and type 2 diabetes.  He has also participated as a co-investigator at the New Mexico site in landmark diabetes-related clinical trials, including the Diabetes Control and Complications Trial (DCCT) and the Diabetes Prevention Program (DPP).  Dr. Burge’s current research is aimed at establishing a comprehensive cohort of prediabetes subjects as a repository for future research studies.  This work is supported by the Centers for Disease Control (CDC) and focuses on New Mexico populations that suffer disproportionately from health disparity.

Dr. Burge served as the longstanding Program Director of the UNM General Clinical Research Center (GCRC) and is currently the Deputy Director of UNM’s new Clinical and Translational Science Center (CTSC). Before that, he served as the Research Subject Advocate for the UNM GCRC, and he is well familiar with Data Safety and Monitoring requirements and the functions of a DSMB in the proposed study.  He has also successfully applied for an IND in the past.  

Dr. Burge is a recent past-President of the American Federation for Medical Research (AFMR) and current President of the Western Society for Clinical Investigation (WSCI).